Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+Breast Cancer

被引：0
|
作者：
Zhang, Ningning
Huang, Yuxin
Wang, Guanwen
Xiang, Yimei
Jing, Zhouhong
Zeng, Junjie
Yu, Feng
Pan, Xianjun
Zhou, Wenqi
Zeng, Xiaohua
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-14-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-14-05
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Association of clinical biomarkers and response to neoadjuvant therapy in breast cancer
    Gerard Feeney
    Ronan Waldron
    Nicola Miller
    Carmel Malone
    Karl Sweeney
    Raymond McLaughlin
    Aoife Lowery
    Kevin Barry
    Michael Kerin
    [J]. Irish Journal of Medical Science (1971 -), 2024, 193 : 605 - 613
  • [42] Genomic alterations associated with HER2+breast cancer risk and clinical outcome in response to trastuzumab
    Singla, Heena
    Kaur, Raman Preet
    Shafi, Gowhar
    Vashistha, Rajesh
    Banipal, Raja Paramjeet Singh
    Kumar, Vinod
    Munshi, Anjana
    [J]. MOLECULAR BIOLOGY REPORTS, 2019, 46 (01) : 823 - 831
  • [43] PPARγ loss increases the metastatic potential of HER2+breast cancer
    Lightbody, Elizabeth D.
    O'Connell, Kathleen M. J.
    Newton, Hailey T.
    Rubino, Rachel R.
    Apostoli, Anthony J.
    Ren, Kevin
    SenGupta, Sandip K.
    Nicol, Christopher J.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [44] The optimal neoadjuvant treatment regimen for HR+/HER2+breast cancer: a network meta-analysis
    Wang, Hao
    Liu, Shiwei
    Yu, Miao
    Mi, Kun
    Mou, Exian
    Xia, Li
    Xie, Weimin
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [45] Optimizing combination therapy in a murine model of HER2+breast cancer?
    Lima, Ernesto A. B. F.
    Wyde, Reid A. F.
    Sorace, Anna G.
    Yankeelov, Thomas E.
    [J]. COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING, 2022, 402
  • [46] Engineered nanomaterials as an effective tool for HER2+breast cancer therapy
    Pandey, Prashant
    Arya, Dilip Kumar
    Ramar, Mohan Kumar
    Chidambaram, Kumarappan
    Rajinikanth, P. S.
    [J]. DRUG DISCOVERY TODAY, 2022, 27 (09) : 2526 - 2540
  • [47] The addition of neoadjuvant pertuzumab for the treatment of HER2+breast cancer: a cost estimate with real-world data
    Borges, Andreia
    Pereira, Filipa
    Redondo, Patricia
    Antunes, Luis
    Vieira, Claudia
    Antunes, Pedro
    Bento, Maria Jose
    Sousa, Susana
    Lopes, Jose Machado
    Rocha-Goncalves, Francisco
    de Sousa, Joaquim Abreu
    Pereira, Deolinda Sousa
    Borges, Marina
    [J]. HEALTH ECONOMICS REVIEW, 2021, 11 (01)
  • [48] Response of HER2+breast cancer patients to allogeneic cell immunotherapy
    Har-Noy, Michael
    Lausoontornsiri, Wirote
    Or, Reuven
    Katsanis, Emmanual
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Adjuvant therapy for HER2+breast cancer: practice, perception, and toxicity
    Rocque, Gabrielle
    Onitilo, Adedayo
    Engel, Jessica
    Pettke, Erica
    Boshoven, Alice
    Kim, KyungMann
    Rishi, Shailly
    Waack, Bonnie
    Wisinski, Kari B.
    Tevaarwerk, Amye
    Burkard, Mark E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 713 - 721
  • [50] Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    [J]. LABORATORY INVESTIGATION, 2019, 99
12345